TELEMED DIABETES

• Abstract
• 2011 CIBERDEM Annual Report
• Press release

Objectives

To evaluate the impact of the Medical Guard Diabetes® telematic system - as a telematic communication system which allows transmitting the results of capillary glucose readings, insulin doses, carbohydrate intake in foods and other events from home or other places to the medical team through a web server- on the effectiveness of financial and clinical management of human resources and materials intended for a program for optimizing metabolic control in patients with type 1 diabetes mellitus, considering the degree of metabolic control and patients’ quality of life.

The Telemed-diabetes study is crucial for comparing the cost and effectiveness parameters of two control optimization programs by means of physical visits or substituting some physical visits by means of a telematic communication system.

Telemed-diabetes is an open, comparative, prospective, randomized, multi-centre study (five participating centres) which will allow knowing the effectiveness and usefulness of the program with telematic communication by means of assessment and comparison between the two groups of participating patients by means of the results of:

• Metabolic control of diabetes: glycated haemoglobin (HbA1c) results and hypoglycaemia and hyperglycaemia seizure frequency.
• Costs of patient visits in: time, expenses incurred for traveling to hospital and failure to carry out daily activity (school, work) due to hospital visit, compared with the costs of medical appointments that do not require physical presence with the aid of the telematic support used.

Calendar

April 2011 - April 2012: Implementation of the Telemed-diabetes study.

Members

• Enric Esmatjes (Hospital Clínic de Barcelona y CIBERDEM) - coordinator
• Oriol Solà (Agència d’Informació, Avaluació i Qualitat en Salut)
• Enric Esmatjes, Margarita Jansà y Daria Roca (Hospital Clínic de Barcelona y CIBERDEM)
• Marisol Ruiz de Adana, Francisca Linares y Mercedes Guerrero (Hospital Carlos Haya-IMABIS, Málaga, y CIBERDEM)
• Federico Vázquez y Anibal Aguayo (Hospital de Cruces, Bilbao, y CIBERDEM)
• Sergio Martínez-Hervás y Nieves Brito (Hospital Clínico de Valencia y CIBERDEM)
• Natalia Pérez-Ferrer y Laura del Valle (Hospital San Carlos de Madrid y CIBERDEM)
• Insight Consulting & Research (Monitorización y seguimiento del estudio) y Pulso Ediciones SL (Sistema telemático Medical Guard Diabetes®)
• Coordination/implementation support Scientific Direction and Head Office CIBERDEM

Sponsor

Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) - Instituto de Salud Carlos III, Ministerio de Economía y Competitividad (Ministerio de Economía y Competitividad) (ISCIII, MINECO).